OBJECTIVE. Thyroid cancer is the most common endocrine cancer. This review evaluates the established use of 18F-FDG PET/CT in papillary, follicular, Hürthle cell, anaplastic, and medullary thyroid cancers. The significance of incidental diffuse and focal thyroid FDG uptake is discussed. The evolving value of non-FDG radiotracers, including 124I, 18F-dihydroxyphenylalanine, and 68Ga somatostatin analogs, is summarized. CONCLUSION. PET/CT is a valuable imaging test, in the appropriate clinical context, for the management of thyroid cancers.
- F-DOPA PET/CT
- FDG PET/CT
- Thyroid cancer
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging